Aplastic Anemia
151
18
24
68
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
33 trials with published results (22%)
Research Maturity
68 completed trials (45% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
7.3%
11 terminated out of 151 trials
86.1%
-0.4% vs benchmark
13%
19 trials in Phase 3/4
49%
33 of 68 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 68 completed trials
Clinical Trials (151)
Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
CK0801 for Treatment of Aplastic Anemia
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia
Revolade Tablets Specified Drug-use Survey
National Longitudinal Cohort of Hematological Diseases
A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.
UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
A Study of Emapalumab for Pediatric Aplastic Anemia
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy